Search Results

The FebriDx® Bacterial/Non-Bacterial Point-of-Care Assay is a qualitative visually read rapid immunoassay for the detection of human host response proteins, Myxovirus resistance protein A (MxA) and C-reactive protein (CRP) directly from fingerstick blood. FebriDx is indicated for use in patients aged 12-64 who present to urgent care or emergency care settings for evaluation of acute respiratory infection who have had symptoms for less than 7 days and within 3 days of fever onset.

FebriDx test results are intended to be used in conjunction with other clinical and diagnostic findings as an aid in the diagnosis of bacterial acute respiratory infection and differentiation from non-bacterial etiology. The assessment of whether a bacterial infection is present should always be based on consideration of all available information, and not based solely on the FebriDx test results. FebriDx test results are not intended to identify a specific pathogen or the severity of infection.

FebriDx External Controls are used in the FebriDx Test as assayed quality control samples to assess the performance and reliability of the FebriDx Test.

FebriDx is a rapid lateral flow immunoassay for the visual, qualitative, in vitro detection of elevated levels of host response proteins, Myxovirus resistance protein A (MxA) and Creactive protein (CRP), directly from fingerstick blood to aid in the evaluation of acute respiratory infections. The single-use, disposable FebriDx test is an all-in-one integrated platform that includes a lateral flow test strip, a built-in retractable safety lancet, blood collection and transfer tube and buffer delivery system. The FebriDx test produces a visualread qualitative result. Operators interpret the test and can visually see whether the infection may be due to a bacterial infection or other non-bacterial etiology.

FebriDx External Controls to monitor performance and reliability of the FebriDx test are sold separately. FebriDx External Controls are a two-vial set with one negative buffer and one positive control containing recombinant CRP and MxA.

The Lumos Diagnostics FebriDx Bacterial / Non-bacterial Point-of-Care Assay is a qualitative visually read rapid immunoassay designed to detect human host response proteins (Myxovirus resistance protein A (MxA) and C-reactive protein (CRP)) from fingerstick blood. It is intended for use in patients aged 12-64 with acute respiratory infection symptoms for less than 7 days and within 3 days of fever onset, presenting to urgent care or emergency care settings. The assay aids in diagnosing bacterial acute respiratory infection and differentiating it from non-bacterial etiology, to be used in conjunction with other clinical and diagnostic findings.

Here's an analysis of the acceptance criteria and the study proving the device meets them:

1. Table of Acceptance Criteria and Reported Device Performance

The provided document does not explicitly state pre-defined acceptance criteria for the clinical performance. However, regulatory bodies typically look for high Positive Percent Agreement (PPA) and Negative Percent Agreement (NPA) to establish substantial equivalence. Based on the clinical study results, the following can be inferred as performance benchmarks.

Note: For microbiologically confirmed bacterial infections, the PPA increased to 100% (33/33) and NPA improved to 91.0% (263/289).

2. Sample Size Used for the Test Set and Data Provenance

• Test Set (Clinical Study):
  • Symptomatic Participants (ARI cohort): 520 participants.
  • Asymptomatic Controls: 170 participants (160 for the NPA analysis).
  • Total Enrolled: 708 participants (520 symptomatic, 170 asymptomatic, 18 withdrawals after consent).
• Data Provenance: The study was a "well-controlled, prospective, multi-center blinded clinical trial conducted in the United States (U.S.)" between October 2019 and April 2021.

3. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications

• Number of Experts: Two independent expert reviewers.
• Qualifications: The document states they were "two independent expert reviewers" but does not explicitly detail their specific qualifications (e.g., "radiologist with 10 years of experience"). However, given the nature of the study (diagnosis of bacterial acute respiratory infection), it can be inferred they are likely medical professionals with expertise in infectious diseases, emergency medicine, or urgent care.

4. Adjudication Method for the Test Set

The adjudication method was based on a "composite Clinical Reference Algorithm" in conjunction with "adjudication by two independent expert reviewers, who were blinded to FebriDx results." This suggests a consensus-based approach where the experts reach a final decision after reviewing all available clinical and laboratory testing data.

5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study was Done

• No, a Multi-Reader Multi-Case (MRMC) comparative effectiveness study was not conducted. The clinical study evaluated the standalone performance of the FebriDx device against a clinical reference algorithm and expert adjudication. It did not involve comparing human readers with and without AI assistance.

6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) was done

• Yes, a standalone performance study was conducted. The "Clinical Performance" section directly assesses the FebriDx device's accuracy (PPA, NPA, etc.) against the adjudicated clinical truth. The device itself is a visually-read rapid immunoassay, implying a human reads the result, but the assessment of its diagnostic accuracy is the "standalone" performance of the assay itself compared to the ground truth. The study reports the performance characteristics of the device's output.

7. The Type of Ground Truth Used

The ground truth, referred to as "Final diagnosis (Clinical Truth)," was based on:

• A composite Clinical Reference Algorithm which incorporated:
  • Pathogen detection testing (e.g., bacterial culture, multiplex PCR for various viruses/bacteria, SARS-CoV-2 PCR, EBV IgM).
  • Measures of host immune response (e.g., Hematology: Complete Blood Cell Count (CBC), B.R.A.H.M.S Procalcitonin).
• Adjudication by two independent expert reviewers who were blinded to the FebriDx results and made a final qualitative diagnosis after review of all clinical and laboratory testing data.
• Outcomes data: Participants admitted to the hospital for pneumonia with objective evidence of bacterial infection were reclassified, indicating that outcomes were a component of confirming or revising the "clinical truth."

8. The Sample Size for the Training Set

The document does not provide information regarding the sample size used for the training set. The descriptions focus on the analytical performance (precision, LoD, hook effect, stability) and the clinical study which serves as the validation/test set for regulatory submission.

9. How the Ground Truth for the Training Set was Established

Since information on a distinct "training set" is not provided, the method for establishing its ground truth is also not specified in this document. It is common for such devices to use internal development or historical data for training, and the clinical study described is the primary validation performed for regulatory submission.

Ask a specific question about this device

The Synovasure Alpha Defensin Lateral Flow Test Kit is a qualitative visually read immunochromatographic assay for the detection of human host response proteins, Alpha Defensins 1-3, in the synovial fluid of adults with a total joint replacement who are being evaluated for revision surgery. The Synovasure Alpha Defensin Lateral Flow Test Kit results are intended to be used in conjunction with other clinical and diagnostic findings as an aid in the diagnosis of periprosthetic joint infection (PJ). The Synovasure Alpha Defensin Lateral Flow Test Kit is not intended to identify the etiology or severity of a PJI.

The Synovasure Alpha Defensin Control Kit is used in the Synovasure Alpha Defensin Lateral Flow Test Kit as assayed quality control samples to monitor performance and reliability of the Synovasure Alpha Defensin Lateral Flow Test Kit.

The Synovasure Alpha Defensin (AD) Lateral Flow (LF) Test Kit is an immunoassay for the detection of alpha defensin levels in the synovial fluid of patients with a potential PJI. Antibodies specific to alpha defensin bind host alpha defensin in the synovial fluid, become immobilized on the lateral flow test strip, and are detected as a colored line due to the use of a colloidal gold reporter.

This document describes the Synovasure Alpha Defensin Lateral Flow Test Kit and its performance.

The device is a qualitative, visually-read immunochromatographic assay for detecting human host response proteins, Alpha Defensins 1-3, in synovial fluid of adults with total joint replacement being evaluated for revision surgery. It is intended to aid in the diagnosis of periprosthetic joint infection (PJI) when used with other clinical and diagnostic findings. It does not identify the etiology or severity of PJI.

Here's an analysis of the provided information regarding acceptance criteria and the study proving the device meets them:

1. A table of acceptance criteria and the reported device performance

The provided document does not explicitly state acceptance criteria in a quantitative table format for the device's performance. Instead, it references a "Method comparison study to demonstrate equivalent performance between proposed device with modified cassette geometry and existing version of the Alpha Defensin Lateral Flow Test Device was performed." This implies that the acceptance criterion was "equivalent performance" to the predicate device. However, specific metrics (e.g., sensitivity, specificity, accuracy) and their target values are not provided within this summary.

Therefore, a table cannot be fully constructed from the provided text. To illustrate, if specific targets were present:

2. Sample size used for the test set and the data provenance (e.g. country of origin of the data, retrospective or prospective)

The document mentions a "Method comparison study," but it does not specify the sample size for this study. It also does not provide information on the data provenance (e.g., country of origin, retrospective or prospective nature of the data).

3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts (e.g. radiologist with 10 years of experience)

The document does not provide information on the number of experts used to establish ground truth or their qualifications. Given that the device detects "human host response proteins" and aids in "diagnosis of periprosthetic joint infection (PJI) ... in conjunction with other clinical and diagnostic findings," the ground truth likely involves clinical diagnosis of PJI, which would typically be established by medical professionals. However, specifics are missing.

4. Adjudication method (e.g. 2+1, 3+1, none) for the test set

The document does not provide information on any adjudication method used for establishing the ground truth or evaluating the device's performance in the method comparison study.

5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance

This device is described as a "qualitative visually read immunochromatographic assay" (a lateral flow test kit) and not an AI-assisted diagnostic tool for image analysis. Therefore, a Multi-Reader Multi-Case (MRMC) comparative effectiveness study evaluating human readers' improvement with AI assistance would not be applicable to this type of device, and no such study is mentioned.

6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done

This is a visually read test kit, implying a human-in-the-loop component for reading the test result. Therefore, a "standalone algorithm only" performance study would not be applicable in the same way it would be for an AI-driven image analysis algorithm. The "method comparison study" likely evaluates the performance of the device itself (including human interpretation) against a reference method or the predicate device.

7. The type of ground truth used (expert consensus, pathology, outcomes data, etc)

The document states the device results "are intended to be used in conjunction with other clinical and diagnostic findings as an aid in the diagnosis of periprosthetic joint infection (PJI)." This strongly suggests that the ground truth for PJI diagnosis was established based on clinical diagnosis, which typically involves an expert consensus of various clinical, laboratory, and imaging findings, and potentially surgical/pathological confirmation. However, the specific components of the ground truth (e.g., specific clinical criteria, culture results, pathology reports) are not detailed.

8. The sample size for the training set

The document describes a "method comparison study" between the proposed device and an existing version. It does not mention a separate "training set" as would be typical for machine learning models. This is likely because the device is a conventional in-vitro diagnostic test, not an AI/ML-based device.

9. How the ground truth for the training set was established

As there is no mention of a "training set" for an AI/ML model, this question is not applicable to the information provided. The "ground truth" for the performance evaluation set is implicitly clinical diagnosis of PJI, as discussed in point 7.

Ask a specific question about this device

The Synovasure Alpha Defensin Lateral Flow Test Kit is a qualitative visually read immunochromatographic assay for the detection of human host response proteins, Alpha Defensins 1-3, in the synovial fluid of adults with a total joint replacement who are being evaluated for revision surgery. The Synovasure Alpha Defensin Lateral Flow Test Kit results are intended to be used in conjunction with other clinical and diagnostic findings as an aid in the diagnosis of periprosthetic joint infection (PJI). The Synovasure Alpha Defensin Lateral Flow Test Kit is not intended to identify the etiology or severity of a PJI.

The Synovasure Alpha Defensin Control Kit is used in the Synovasure Alpha Defensin Lateral Flow Test Kit as assayed quality control samples to monitor performance and reliability of the Synovasure Alpha Defensin Lateral Flow Test Kit.

The Synovasure Alpha Defensin Lateral Flow Test Kit (Synovasure LFT) is an immunoassay for the detection of alpha defensin levels in the synovial fluid of patients with a potential PJI. Antibodies specific to alpha defensin bind host alpha defensin in the synovial fluid, become immobilized on the lateral flow test strip, and are detected as a colored line due to the use of a colloidal gold reporter.

Synovasure Alpha Defensin Lateral Flow Test Kit contains two sub components:

• 1. Synovasure Alpha Defensin Lateral Flow Test Device
• 2. Synovasure Lateral Flow Sample Prep Assembly

The Synovasure Lateral Flow Sample Prep Assembly further contains

• 1. One Synovasure Dilution Buffer Bottle
• 2. One Sample Cup
• 3. Two Microsafe Tubes

The Synovasure Alpha Defensin Lateral Flow Test Device is a cassette that includes a reagent strip. Each cassette contains a reagent strip with all the critical components for the assay.

The Synovasure Alpha Defensin Lateral Flow Test Kit is accompanied by the Synovasure Alpha Defensin Control Kit. The Synovasure Alpha Defensin Control Kit further contains

• 1. Synovasure Alpha Defensin Positive Control
• 2. Synovasure Alpha Defensin Negative Control
• 3. Synovasure Control Reconstitution Bottle

The positive control contains 0.25 mL of 16 µg/mL alpha defensin in synthetic synovial fluid and the negative control contains 0.25 mL of synthetic synovial fluid.

Additional materials required but not provided include

1. Timer

Here's a breakdown of the acceptance criteria and the study proving the device meets them, based on the provided text:

1. Table of Acceptance Criteria and Reported Device Performance

The core clinical acceptance criteria for the Synovasure Alpha Defensin Lateral Flow Test Kit's performance in diagnosing periprosthetic joint infection (PJI) are related to its sensitivity and specificity.

Notes on Acceptance Criteria Met: The device met the specificity criterion in the prospective study (94.8% with 91.2% LCB, exceeding the >90% and >90% LCB requirement). The device did not fully meet the sensitivity criterion in the prospective study (89.5% with 78.5% LCB), as the lower confidence bound of 78.5% is below the required >85%. However, the sponsor appears to have supplemented this with retrospective data to support overall performance for the De Novo classification.

2. Sample Sizes and Data Provenance

• Test Set Sample Size:

  • Prospective Study: 305 synovial fluid samples.
  • Retrospective Study: 65 fresh remnant synovial fluid samples.
  • Total Clinical Test Set: 370 samples (305 prospective + 65 retrospective).

• Data Provenance:

  • Country of Origin: United States (Prospective study conducted at 3 US medical centers).
  • Retrospective/Prospective: Both.
    • The main clinical study was a prospective study.
    • A retrospective collection of fresh remnant samples was used to supplement the prospective data and reach a target of at least 100 positive specimens.

3. Number of Experts and their Qualifications for Ground Truth

• Number of Experts: A two-physician panel was used to adjudicate the final MSIS status for prospective data. A third physician was consulted to resolve discrepant opinions.
• Qualifications of Experts: The document states "two-physician panel" and "third physician," implying medical doctors, but does not specify their specialties (e.g., orthopedic surgeons, infectious disease specialists) or years of experience.

4. Adjudication Method for the Test Set

• Adjudication Method: 2+1 adjudication.
  • The "final status determination was adjudicated by a two-physician panel, with discrepant opinions being resolved by consultation of a third physician."

5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study

• Was an MRMC study done?: No, an MRMC comparative effectiveness study was not mentioned or conducted as this is a qualitative visually-read lateral flow immunoassay device, not an AI or imaging-based diagnostic where human reader performance would be a primary variable. The output is a visual line or no line, reducing inter-reader variability compared to complex interpretations.

• Effect Size of Human Readers with AI vs. without AI assistance: Not applicable, as no AI assistance is involved in the interpretation of this device.

6. Standalone Performance Study (Algorithm Only)

• Was a standalone performance study done?: Not applicable in the context of an algorithm. This device is a manual, visually-read lateral flow immunoassay. Its "standalone performance" is essentially its analytical and clinical performance as a device read directly by an operator, which is what the provided sensitivity and specificity figures represent. There is no separate "algorithm" for this product that would operate without human interaction (as it is a visually-read test).

7. Type of Ground Truth Used

• Type of Ground Truth: Expert Consensus using established clinical criteria.
  • The ground truth for Periprosthetic Joint Infection (PJI) was established using the Musculoskeletal Infection Society (MSIS) criteria.
  • For the prospective study, the final MSIS status was adjudicated by a two-physician panel with a third physician for conflicts.
  • For the retrospective samples, the ground truth was based on a "status determination based positive confirmation of three minor MSIS criteria (neutrophil %, positive culture, and WBC count)."

8. Sample Size for the Training Set

• Training Set Sample Size: The document does not explicitly mention a separate "training set" for an algorithm or model. This is consistent with the nature of a lateral flow immunoassay, which does not typically involve machine learning or AI models that require distinct training sets. The studies described are performance validation studies.

9. How the Ground Truth for the Training Set was Established

• Ground Truth Establishment for Training Set: Not applicable, as no distinct training set for an algorithm or machine learning model is described for this device.

Ask a specific question about this device